Xoma's bone marrow immunotoxin
Executive Summary
Firm reports results of an initial clinical test of monoclonal antibody-based immunotoxin Xomazyme-Lym for treatment of graft versus host disease, a complication of bone marrow transplantation. Xoma says one patient in the study, a 10-year old girl, demonstrated reversal of GVHD after treatment with the drug. The first monoclonal antibody approved by FDA for therapeutic use, Ortho's Orthoclone OKT 3, was for reversal of actue kidney transplant rejection.
|
Firm reports results of an initial clinical test of monoclonal
antibody-based immunotoxin Xomazyme-Lym for treatment of
graft versus host disease, a complication of bone marrow
transplantation. Xoma says one patient in the study, a 10-year old
girl, demonstrated reversal of GVHD after treatment with the drug.
The first monoclonal antibody approved by FDA for therapeutic use,
Ortho's Orthoclone OKT 3, was for reversal of actue kidney
transplant rejection. |